SIGA's smallpox vaccine to enter Ph II trials
The USA's SIGA Technologies says that its lead smallpox drug candidate, SIGA-246, has successfully completed the first planned human clinical safety trial. According to the New York-based firm, preliminary results indicate that the agent is "safe and well-tolerated" in human volunteers at all tested oral doses. In addition, data from blood level exposure was sufficient to support once-daily dosing.
Dennis Hruby, SIGA's chief scientific officer, said that the data obtained from this Phase I double-blind, randomized, placebo-controlled, ascending single-dose study will be used to support and design the upcoming multiple-dose trial.
The US drugmaker believes that SIGA-246 is the most advanced smallpox treatment currently in development, representing a new approach towards an orally-active, antiviral therapeutic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze